Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
If they dont get approval, they might sell Iclaprim. It was sold already 3 times, so the price might be not be so high (below current marketcap). But in general, I strongly expect them to get the approval...
They are financed till they get the minutes. If it make sence to invest further to gain approval, they need to raise more money after the minutes. So explain me, why you need an annual report or a stratey?
Strategy is, to get the approval. They have an FDA meeting on the 3rd of may. After that the FDA has up to 30 days to send the minutes to Motif. Than they well know more and we get informed...
Please read the last RNS...
exactly, thats why we wont hear anything till 3rd. of June...
Till the 3rd of June, is a very long time. Everything is said and discussed. Would expect some volatility and nervous trading after the 3rd of may, as any direction the stock trades, will get interpreted as some leak out of the meeting with the FDA. Expect range trading 3-9p over the next weeks?
Right, and Arpida had an Adcom before...
Arpidas comments after the rejection were, that they want to continue to research iclaprim. Which wouldnt make sense at all.I can´t imagine that Lumsden would have bought the drug with these FDA comments. ColdFishPie can you occupy that with reports ??
In my opinion iclaprim was not rejected with the comment it should not be pursued any further. Wasnt it the case, Arpida did not adhere to the requirements of the fda and therefore new studies should be carried out, which could then not be financed? That's a big difference. I have never read, the FDA recommended that the development should not be followed up that time.
The big institutions didnt participate, otherwise Peel Hunt would have done it. The position in their fund is propably that small, they just hold and see, otherwise, they book it out for nothing. They are not allowed to play such risky games, after what happened. SP Angel placed the 45mln much better, than Peel Hunt before. The last capital increase with Peel Hunt was done at 31p, when the stock did trade at 38-39!!! If I remeber right and a few days later, the stock traded below 31p... i am disapointed by the management about their financial behaviour, but have hope the science will make it. Thats why I bought a few and will average down, if we trade at 5 or below.
A new NDA could cost 2-2.5mln? That was the amount they safed the last time.
Bringing a company into such a financial position, constantly alerting the market about the need for liquidity, etc... I have never seen that before at any other company and they also have regulatory requirements. Instead of simply completing the placement, they warned 3x and I guess they wonder now why the price is so deep. What kind of advisors do they have?? Interim CFO ...
30 days after the Meeting, Motif gets the minutes and will release the outcome.
3rd of June earliest...
Its not that easy as you think...
Lets face it, if they cant get the financing done till June - its game over here!!! Or do you belive there is a pharmacompany out there who is buying iclaprim, which was 3xtimes sold and still in trouble?? Not for 20mln.... this is very bearish and I think it will not be the case - hopefully
If you look at todays trading, it shows that the posts about American II's yesterday, where rubbish. We have to solve it on our own..
Lets all hope, the funding issue is over soon. With the recent hype in the stock, they should be able to get at least 2-3 mln. If not, we have another bigger problem.
Any thoughts, if they cant place 3mln GBP at 5p? What would happen than? At the moment, you cant exclude anything. I doubt an II will participate. But think they should be able to place that amount.
Ian, Im with you on your arguments long term. For the next few weeks/momths I have my doubts. First we need to be financed till June/July. Than we need to see what the FDA says and than I do expect a revaluation. I doubt we see 15p before June.